# Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

> **NCT01715805** · PHASE3 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 1022 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Placebo
- **DRUG:** Antidepressant Therapy (ADT)

## Key facts

- **NCT ID:** NCT01715805
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-15
- **Primary completion:** 2016-06-24
- **Final completion:** 2016-06-24
- **Target enrollment:** 1022 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01715805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01715805, "Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01715805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*